FINWIRES · TerminalLIVE
FINWIRES

CSPC Pharma's Depression Drug Meets Primary Endpoint in Phase 3 Trial

By

CSPC Pharmaceutical (HKG:1093) said its Phase 3 clinical trial of Ammoxetine Hydrochloride Enteric-coated Tablets met its primary endpoint in patients with depression, according to a Monday filing with the Hong Kong bourse.

The trial showed the drug significantly improved Montgomery-Åsberg Depression Rating Scale (MADRS) scores after eight weeks of treatment compared with placebo and was numerically superior to the active control.

HA1406 also demonstrated favorable trends across multiple secondary endpoints and a good safety profile, the company said.

Related Articles

Asia

Cauldron Energy Receives Further Passive Seismic Interpretations at Yanrey Uranium Project; Shares Down 7%

Cauldron Energy (ASX:CXU) said Southern Geoscience has provided a further installment of processed passive seismic interpretations for its Yanrey Uranium Project in Western Australia, covering the Manyingee Southeast, Manyingee West, Ashburton East and Cosgrove locations, according to a Monday Australian bourse filing.The company said the most significant finding from the third installment is the delineation of a separate, previously undiscovered and untested arm of the Manyingee South palaeochannel, with passive seismic continuing to prove a cost-effective method for identifying the margins of palaeochannels and increasing drilling effectiveness.The company's shares fell almost 7% in recent Monday trade.

ASX:CXU
Asia

Infoline Tec Group Seeks Shareholder Nod to Acquire Buildings for New Head Office

Infoline Tec Group (KLSE:INFOTEC) is seeking shareholders' approval for its wholly-owned subsidiary, Infoline IT Solutions, to acquire two adjoining intermediate units from Huayi (SEA) and Orionis Technology, respectively, for a total of 18.6 Malaysian ringgit, according to a Monday filing to Bursa Malaysia.The investor approval will be sought at the upcoming extraordinary general meeting on Aug. 28.The company's shares were down nearly 6% in recent trade.The acquired units will be used to set up the company's new head office. Both acquisitions will be done on a 99-year lease up to Oct. 18, 2106.Infoline's board is also seeking shareholders' nod for a proposed employees' share option scheme (ESOS) covering up to 10% of issued share capital for eligible directors and employees. The scheme will be valid for five years with an option for a further five-year extension.

KLSE:INFOTEC
Asia

Hanwha Aerospace Secures Framework Supply Contract in South Korea

Hanwha Aerospace (KRX:012450) secured a framework contract with an unnamed entity to supply aerospace products, exceeding 2.5% of its most recent annual sales, according to a Monday filing with the Korea Exchange.The company said that the contract is subject to disclosure requirements, and the details of the agreement are withheld due to business confidentiality.

KRX:012450